SFJ PROPEL3
19 Apr 2022
PROPEL-36
NCT04969861
BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)
Nektar Therapeutics
Cancer Type | Head and Neck |
---|---|
Trial Type | Treatment |
Phase | Phase II; Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
Anticipated Start Date | 2022-03-09 |
Anticipated End Date | 2026-05-01 |
Hospital | Cancer Research SA |
---|---|
Clinical Trial Coordinator | Kelly Mead |
admin@cancerresearchsa.com.au | |
Phone | 08 8359 2565 |
Principal Investigator | Dr Sarwan Bishnoi |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs